{"protocolSection":{"identificationModule":{"nctId":"NCT00365716","orgStudyIdInfo":{"id":"V501-007"},"secondaryIdInfos":[{"id":"2006_516"}],"organization":{"fullName":"Merck Sharp & Dohme LLC","class":"INDUSTRY"},"briefTitle":"Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED)","officialTitle":"A Placebo-Controlled, Dose-Ranging Study of Quadrivalent HPV Virus-Like Particle (VLP) Vaccine in 16- to 23-Year-Old Women"},"statusModule":{"statusVerifiedDate":"2015-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2000-05"},"primaryCompletionDateStruct":{"date":"2004-05","type":"ACTUAL"},"completionDateStruct":{"date":"2009-09","type":"ACTUAL"},"studyFirstSubmitDate":"2006-08-16","studyFirstSubmitQcDate":"2006-08-16","studyFirstPostDateStruct":{"date":"2006-08-17","type":"ESTIMATED"},"resultsFirstSubmitDate":"2010-05-19","resultsFirstSubmitQcDate":"2010-07-06","resultsFirstPostDateStruct":{"date":"2010-08-03","type":"ESTIMATED"},"lastUpdateSubmitDate":"2015-10-06","lastUpdatePostDateStruct":{"date":"2015-10-07","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Merck Sharp & Dohme LLC","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"This study was conducted in 2 parts. Part A was a randomized, double-blind, placebo-controlled, multicenter, sequential dose-escalating evaluation. Part B was a randomized, double-blind (operating under in-house blinding procedures), placebo-controlled, multicenter, dose-ranging study."},"conditionsModule":{"conditions":["Papillomavirus Infections","Genital Diseases, Female"],"keywords":["HPV 6/11/16/18 infection and related genital disease"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":1158,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine","type":"EXPERIMENTAL","description":"The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 1 received a 20/40/40/20 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.","interventionNames":["Biological: Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20/40/40/20"]},{"label":"Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40","type":"EXPERIMENTAL","description":"The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 2 received a 40/40/40/40 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.","interventionNames":["Biological: Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40"]},{"label":"Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80","type":"EXPERIMENTAL","description":"The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 3 received a 80/80/40/80 formulation of quadrivalent human papillomavirus (qHPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.","interventionNames":["Biological: Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80"]},{"label":"Placebo (mcg) (Aluminum Adjuvant) 225","type":"EXPERIMENTAL","description":"The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 4 received placebo containing 225 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.","interventionNames":["Biological: Placebo (mcg) (Aluminum Adjuvant)225"]},{"label":"Placebo (mcg) (Aluminum Adjuvant) 450","type":"EXPERIMENTAL","description":"The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 5 received placebo containing 450 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.","interventionNames":["Biological: Placebo (mcg) (Aluminum Adjuvant) 450"]}],"interventions":[{"type":"BIOLOGICAL","name":"Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20/40/40/20","description":"20/40/40/20 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.","armGroupLabels":["Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine"],"otherNames":["V501"]},{"type":"BIOLOGICAL","name":"Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40","description":"40/40/40/40 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.","armGroupLabels":["Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40"],"otherNames":["V501"]},{"type":"BIOLOGICAL","name":"Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80","description":"80/80/40/80 formulation of quadrivalent human papillomavirus (qHPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.","armGroupLabels":["Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80"],"otherNames":["V501"]},{"type":"BIOLOGICAL","name":"Placebo (mcg) (Aluminum Adjuvant)225","description":"placebo containing 225 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.","armGroupLabels":["Placebo (mcg) (Aluminum Adjuvant) 225"]},{"type":"BIOLOGICAL","name":"Placebo (mcg) (Aluminum Adjuvant) 450","description":"placebo containing 450 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.","armGroupLabels":["Placebo (mcg) (Aluminum Adjuvant) 450"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Subjects With Injection Site Adverse Experiences","timeFrame":"Days 1-5 following any vaccination visit"}],"secondaryOutcomes":[{"measure":"Incidence of HPV 6-, 11-, 16- or 18-related Persistent Infection or Disease (Cervical Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia, Vaginal Intraepithelial Neoplasia, Adenocarcinoma in Situ, Cervical Cancer, and Genital Warts)","timeFrame":"Through 36 Months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy females 16 to 23 years of age\n* Not pregnant at enrollment and must have agreed to use effective contraception through Month 7 of the study\n* Lifetime history of 0 to 4 male sexual partners (individuals with whom penetrative sexual intercourse occurred)\n\nExclusion Criteria:\n\n* No prior receipt of an Human Papillomavirus (HPV) vaccine\n* No receipt of inactivated or recombinant vaccines within 14 days prior to enrollment or receipt of live vaccines within 21 days prior to enrollment\n* No prior abnormal Pap test showing squamous intraepithelial lesion (SIL) or biopsy showing cervical intraepithelial neoplasia (CIN)\n* No prior history of genital warts or treatment for genital warts","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"16 Years","maximumAge":"23 Years","stdAges":["CHILD","ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Monitor","affiliation":"Merck Sharp & Dohme LLC","role":"STUDY_DIRECTOR"}]},"referencesModule":{"references":[{"pmid":"15863374","type":"BACKGROUND","citation":"Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005 May;6(5):271-8. doi: 10.1016/S1470-2045(05)70101-7."},{"pmid":"16753240","type":"BACKGROUND","citation":"Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP, Brown DR, Ferenczy A, Harper DM, Koutsky LA, Kurman RJ, Lehtinen M, Malm C, Olsson SE, Ronnett BM, Skjeldestad FE, Steinwall M, Stoler MH, Wheeler CM, Taddeo FJ, Yu J, Lupinacci L, Railkar R, Marchese R, Esser MT, Bryan J, Jansen KU, Sings HL, Tamms GM, Saah AJ, Barr E. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine. 2006 Jul 7;24(27-28):5571-83. doi: 10.1016/j.vaccine.2006.04.068. Epub 2006 May 15."},{"pmid":"17117182","type":"BACKGROUND","citation":"Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, Olsson SE, Hoye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, Krogh Gv, Lehtinen M, Malm C, Tamms GM, Giacoletti K, Lupinacci L, Railkar R, Taddeo FJ, Bryan J, Esser MT, Sings HL, Saah AJ, Barr E. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006 Dec 4;95(11):1459-66. doi: 10.1038/sj.bjc.6603469. Epub 2006 Nov 21."},{"pmid":"18313445","type":"BACKGROUND","citation":"Barr E, Gause CK, Bautista OM, Railkar RA, Lupinacci LC, Insinga RP, Sings HL, Haupt RM. Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women. Am J Obstet Gynecol. 2008 Mar;198(3):261.e1-11. doi: 10.1016/j.ajog.2007.09.001."},{"pmid":"17512854","type":"BACKGROUND","citation":"Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Garland SM, Harper DM, Tang GW, Ferris DG, Steben M, Jones RW, Bryan J, Taddeo FJ, Bautista OM, Esser MT, Sings HL, Nelson M, Boslego JW, Sattler C, Barr E, Paavonen J. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet. 2007 May 19;369(9574):1693-702. doi: 10.1016/S0140-6736(07)60777-6."},{"pmid":"18000825","type":"BACKGROUND","citation":"Perez G, Lazcano-Ponce E, Hernandez-Avila M, Garcia PJ, Munoz N, Villa LL, Bryan J, Taddeo FJ, Lu S, Esser MT, Vuocolo S, Sattler C, Barr E. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women. Int J Cancer. 2008 Mar 15;122(6):1311-8. doi: 10.1002/ijc.23260."},{"pmid":"17499406","type":"BACKGROUND","citation":"Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, Iversen OE, Hoye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, von Krogh G, Lehtinen M, Paavonen J, Tamms GM, Giacoletti K, Lupinacci L, Esser MT, Vuocolo SC, Saah AJ, Barr E. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine. 2007 Jun 21;25(26):4931-9. doi: 10.1016/j.vaccine.2007.03.049. Epub 2007 Apr 20."},{"pmid":"17611417","type":"BACKGROUND","citation":"Smith JF, Brownlow M, Brown M, Kowalski R, Esser MT, Ruiz W, Barr E, Brown DR, Bryan JT. Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions. Hum Vaccin. 2007 Jul-Aug;3(4):109-15. doi: 10.4161/hv.3.4.4058. Epub 2007 Feb 24."},{"pmid":"17544766","type":"BACKGROUND","citation":"Ault KA; Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007 Jun 2;369(9576):1861-1868. doi: 10.1016/S0140-6736(07)60852-6."},{"pmid":"17955433","type":"BACKGROUND","citation":"Giuliano AR, Lazcano-Ponce E, Villa L, Nolan T, Marchant C, Radley D, Golm G, McCarroll K, Yu J, Esser MT, Vuocolo SC, Barr E. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine. J Infect Dis. 2007 Oct 15;196(8):1153-62. doi: 10.1086/521679. Epub 2007 Sep 17."},{"pmid":"41276263","type":"DERIVED","citation":"Bergman H, Henschke N, Arevalo-Rodriguez I, Buckley BS, Crosbie EJ, Davies JC, Dwan K, Golder SP, Loke YK, Probyn K, Petkovic J, Villanueva G, Morrison J. Human papillomavirus (HPV) vaccination for the prevention of cervical cancer and other HPV-related diseases: a network meta-analysis. Cochrane Database Syst Rev. 2025 Nov 24;11(11):CD015364. doi: 10.1002/14651858.CD015364.pub2."}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20/40/40/20","description":"The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 1 received a 20/40/40/20 formulation of quadrivalent human papillomavirus (qHPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.\n\nThe Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the HPV 16 VLP Vaccine or placebo from completion of the Vaccination Period at Month 7 through Month 36."},{"id":"FG001","title":"Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40","description":"The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 2 received a 40/40/40/40 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.\n\nThe Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the HPV 16 VLP Vaccine or placebo from completion of the Vaccination Period at Month 7 through Month 36."},{"id":"FG002","title":"Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80","description":"The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 3 received a 80/80/40/80 formulation of quadrivalent human papillomavirus (qHPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.\n\nThe Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the qHPV 16 VLP Vaccine or placebo from completion of the Vaccination Period at Month 7 through Month 36."},{"id":"FG003","title":"Placebo (mcg) (Aluminum Adjuvant) 225","description":"The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 4 received placebo containing 225 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.\n\nThe Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the qHPV 16 VLP Vaccine or placebo from completion of the Vaccination Period at Month 7 through Month 36."},{"id":"FG004","title":"Placebo (mcg) (Aluminum Adjuvant) 450","description":"The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 5 received placebo containing 450 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.\n\nThe Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the qHPV 16 VLP Vaccine or placebo from completion of the Vaccination Period at Month 7 through Month 36."},{"id":"FG005","title":"Extension 1","description":"This group includes 241 international subjects, who either: (1) received placebo during the base study and continued in the Extension to receive a dose of GARDASIL (20/40/40/20 mcg formulation of qHPV vaccine) at Month 60 (plus 2 and 3 at Months 62 and 66, respectively, (2) received 3 doses of GARDASIL during the Base study and continued into the Extension to receive a fourth dose of GARDASIL at Month 60 for the purposes of investigating whether a fourth dose of vaccine (administered \\~4.5 years following completion of a 3-dose primary regimen) induces HPV 6, 11, 16, and 18 antibody responses that characterize immune therapy."},{"id":"FG006","title":"Extension 2","description":"This group includes 17 subjects from the United States, who received placebo during the base study and received 3 doses of qHPV vaccine during the Extension, or received less than 3 doses of the qHPV Vaccine during the base study and completed the dose regimen during the Extension."}],"periods":[{"title":"Base Study (Day 1 to Month 7)","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"290"},{"groupId":"FG001","numSubjects":"284"},{"groupId":"FG002","numSubjects":"292"},{"groupId":"FG003","numSubjects":"146"},{"groupId":"FG004","numSubjects":"146"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"269"},{"groupId":"FG001","numSubjects":"260"},{"groupId":"FG002","numSubjects":"271"},{"groupId":"FG003","numSubjects":"136"},{"groupId":"FG004","numSubjects":"139"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"21"},{"groupId":"FG001","numSubjects":"24"},{"groupId":"FG002","numSubjects":"21"},{"groupId":"FG003","numSubjects":"10"},{"groupId":"FG004","numSubjects":"7"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Randomized Not Vaccinated","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"4"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}]},{"type":"Pregnancy","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"9"},{"groupId":"FG002","numSubjects":"12"},{"groupId":"FG003","numSubjects":"4"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}]}]},{"title":"Long Term Follow-up (Month 7 toMonth 36)","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"269"},{"groupId":"FG001","numSubjects":"260"},{"groupId":"FG002","numSubjects":"271"},{"groupId":"FG003","numSubjects":"136"},{"groupId":"FG004","numSubjects":"139"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"137"},{"groupId":"FG001","numSubjects":"245"},{"groupId":"FG002","numSubjects":"251"},{"groupId":"FG003","numSubjects":"57"},{"groupId":"FG004","numSubjects":"57"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"132"},{"groupId":"FG001","numSubjects":"15"},{"groupId":"FG002","numSubjects":"20"},{"groupId":"FG003","numSubjects":"79"},{"groupId":"FG004","numSubjects":"82"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Proceeded to Extension 1","reasons":[{"groupId":"FG000","numSubjects":"114"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"69"},{"groupId":"FG004","numSubjects":"75"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"4"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}]},{"type":"Moved","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"13"},{"groupId":"FG003","numSubjects":"4"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}]}]},{"title":"Extension 1","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"241"},{"groupId":"FG006","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"219"},{"groupId":"FG006","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"22"},{"groupId":"FG006","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"9"},{"groupId":"FG006","numSubjects":"0"}]},{"type":"Moved","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"4"},{"groupId":"FG006","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"3"},{"groupId":"FG006","numSubjects":"0"}]},{"type":"Pregnancy","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"4"},{"groupId":"FG006","numSubjects":"0"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"}]}]},{"title":"Extension 2","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","comment":"17 Participants continued into Extension 2 from Extension 1","numSubjects":"17"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"7"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"10"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"2"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"3"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"5"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20/40/40/20","description":"The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 1 received a 20/40/40/20 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.\n\nThe Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the HPV 16 VLP Vaccine or placebo from completion of the Vaccination Period at Month 7 through Month 36."},{"id":"BG001","title":"Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40","description":"The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 2 received a 40/40/40/40 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.\n\nThe Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the HPV 16 VLP Vaccine or placebo from completion of the Vaccination Period at Month 7 through Month 36."},{"id":"BG002","title":"Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80","description":"The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 3 received a 80/80/40/80 formulation of quadrivalent human papillomavirus (qHPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.\n\nThe Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the qHPV 16 VLP Vaccine or placebo from completion of the Vaccination Period at Month 7 through Month 36."},{"id":"BG003","title":"Placebo (mcg) (Aluminum Adjuvant) 225","description":"The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 4 received placebo containing 225 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.\n\nThe Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the qHPV 16 VLP Vaccine or placebo from completion of the Vaccination Period at Month 7 through Month 36."},{"id":"BG004","title":"Placebo (mcg) (Aluminum Adjuvant) 450","description":"The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 5 received placebo containing 450 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.\n\nThe Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the qHPV 16 VLP Vaccine or placebo from completion of the Vaccination Period at Month 7 through Month 36."},{"id":"BG005","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"290"},{"groupId":"BG001","value":"284"},{"groupId":"BG002","value":"292"},{"groupId":"BG003","value":"146"},{"groupId":"BG004","value":"146"},{"groupId":"BG005","value":"1158"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"FULL_RANGE","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"20.2","lowerLimit":"16","upperLimit":"23"},{"groupId":"BG001","value":"20.0","lowerLimit":"15","upperLimit":"24"},{"groupId":"BG002","value":"20.1","lowerLimit":"16","upperLimit":"23"},{"groupId":"BG003","value":"20.0","lowerLimit":"16","upperLimit":"23"},{"groupId":"BG004","value":"20.1","lowerLimit":"13","upperLimit":"23"},{"groupId":"BG005","value":"20.0","lowerLimit":"13","upperLimit":"24"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"290"},{"groupId":"BG001","value":"284"},{"groupId":"BG002","value":"292"},{"groupId":"BG003","value":"146"},{"groupId":"BG004","value":"146"},{"groupId":"BG005","value":"1158"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"5"},{"groupId":"BG005","value":"34"}]}]},{"title":"Black","categories":[{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"27"},{"groupId":"BG003","value":"12"},{"groupId":"BG004","value":"7"},{"groupId":"BG005","value":"103"}]}]},{"title":"Hispanic American","categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"10"},{"groupId":"BG004","value":"11"},{"groupId":"BG005","value":"61"}]}]},{"title":"Indian","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"2"}]}]},{"title":"Multi-racial","categories":[{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"39"}]}]},{"title":"Native American","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"9"}]}]},{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"228"},{"groupId":"BG001","value":"213"},{"groupId":"BG002","value":"240"},{"groupId":"BG003","value":"111"},{"groupId":"BG004","value":"118"},{"groupId":"BG005","value":"910"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects With Injection Site Adverse Experiences","populationDescription":"All vaccinated subjects with adverse experience follow-up.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Days 1-5 following any vaccination visit","groups":[{"id":"OG000","title":"Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20/40/40/20","description":"The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 1 received a 20/40/40/20 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.\n\nThe Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the HPV 16 VLP Vaccine or placebo from completion of the Vaccination Period at Month 7 through Month 36."},{"id":"OG001","title":"Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40","description":"The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 2 received a 40/40/40/40 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.\n\nThe Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the HPV 16 VLP Vaccine or placebo from completion of the Vaccination Period at Month 7 through Month 36."},{"id":"OG002","title":"Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80","description":"The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 3 received a 80/80/40/80 formulation of quadrivalent human papillomavirus (qHPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.\n\nThe Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the qHPV 16 VLP Vaccine or placebo from completion of the Vaccination Period at Month 7 through Month 36."},{"id":"OG003","title":"Placebo (mcg) (Aluminum Adjuvant) 225","description":"The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 4 received placebo containing 225 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.\n\nThe Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the qHPV 16 VLP Vaccine or placebo from completion of the Vaccination Period at Month 7 through Month 36."},{"id":"OG004","title":"Placebo (mcg) (Aluminum Adjuvant) 450","description":"The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 5 received placebo containing 450 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.\n\nThe Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the qHPV 16 VLP Vaccine or placebo from completion of the Vaccination Period at Month 7 through Month 36."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"288"},{"groupId":"OG001","value":"282"},{"groupId":"OG002","value":"292"},{"groupId":"OG003","value":"146"},{"groupId":"OG004","value":"146"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"247"},{"groupId":"OG001","value":"248"},{"groupId":"OG002","value":"266"},{"groupId":"OG003","value":"107"},{"groupId":"OG004","value":"115"}]}]}]},{"type":"SECONDARY","title":"Incidence of HPV 6-, 11-, 16- or 18-related Persistent Infection or Disease (Cervical Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia, Vaginal Intraepithelial Neoplasia, Adenocarcinoma in Situ, Cervical Cancer, and Genital Warts)","populationDescription":"Per-protocol population: subjects must have no major protocol violations, must be seronegative at Day 1 and PCR negative through Month 7 to the relevant HPV type, and must provide follow-up data after Month 7","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Incidence per 100 person-years","timeFrame":"Through 36 Months","groups":[{"id":"OG000","title":"Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20/40/40/20","description":"The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 1 received a 20/40/40/20 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.\n\nThe Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the HPV 16 VLP Vaccine or placebo from completion of the Vaccination Period at Month 7 through Month 36."},{"id":"OG001","title":"Placebo (mcg) (Aluminum Adjuvant) 225 or 450 Combined","description":"For the purposes of this outcome measure, the placebo groups (225 mcg and 450 mcg) were combined."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"235"},{"groupId":"OG001","value":"233"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7"},{"groupId":"OG001","value":"6.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Vaccine Efficacy","paramValue":"89.5","ciPctValue":"95","ciLowerLimit":"70.7","ciUpperLimit":"97.3","estimateComment":"Vaccine Efficacy (% relative risk reduction)\n\nConfidence Interval based on binomial tail probabilities and not from a dispersion parameter."}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Adverse events (AEs) were collected from Day 1 until Month 7. AEs were collected on the subject's vaccination report card daily for 14 days after each injection.","description":"Subjects were observed for 30 minutes after each vaccination. Temperatures were recorded for 5 days after each injection (4 hours after injection and daily for the next 4 days). At Months 2, 3, 6, and 7, subjects were solicited for any gynecological health concerns and any SAEs that had occurred.","eventGroups":[{"id":"EG000","title":"Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20/40/40/20","description":"The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 1 received a 20/40/40/20 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.\n\nThe Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the HPV 16 VLP Vaccine or placebo from completion of the Vaccination Period at Month 7 through Month 36.\n\n* There was one subject randomized to the quadrivalent HPV (Types 6, 11, 16, 18) L1 VLP vaccine 20/40/40/20 mcg group who received the 225 mcg aluminum adjuvant placebo at the third vaccination visit. This subject was not included in the counts reported in the Adverse Event tables. No SAEs were reported for this subject.\n* There was 1 patient that was randomized, but never vaccinated. As such, that patient is not included in this table.","seriousNumAffected":3,"seriousNumAtRisk":288,"otherNumAffected":245,"otherNumAtRisk":288},{"id":"EG001","title":"Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40","description":"The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 2 received a 40/40/40/40 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.\n\nThe Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the HPV 16 VLP Vaccine or placebo from completion of the Vaccination Period at Month 7 through Month 36.\n\n* There were 2 patients from the 40/40/40/40 group that were randomized, but were never vaccinated. As such, these 2 patients are not included in this table.","seriousNumAffected":0,"seriousNumAtRisk":282,"otherNumAffected":247,"otherNumAtRisk":282},{"id":"EG002","title":"Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80","description":"The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 3 received a 80/80/40/80 formulation of quadrivalent human papillomavirus (qHPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.\n\nThe Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the qHPV 16 VLP Vaccine or placebo from completion of the Vaccination Period at Month 7 through Month 36.","seriousNumAffected":2,"seriousNumAtRisk":292,"otherNumAffected":263,"otherNumAtRisk":292},{"id":"EG003","title":"Placebo (mcg) (Aluminum Adjuvant) 225","description":"The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 4 received placebo containing 225 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.\n\nThe Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the qHPV 16 VLP Vaccine or placebo from completion of the Vaccination Period at Month 7 through Month 36.","seriousNumAffected":0,"seriousNumAtRisk":146,"otherNumAffected":105,"otherNumAtRisk":146},{"id":"EG004","title":"Placebo (mcg) (Aluminum Adjuvant) 450","description":"The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 5 received placebo containing 450 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.\n\nThe Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the qHPV 16 VLP Vaccine or placebo from completion of the Vaccination Period at Month 7 through Month 36.","seriousNumAffected":3,"seriousNumAtRisk":146,"otherNumAffected":114,"otherNumAtRisk":146},{"id":"EG005","title":"Extensions","description":"This group includes 241 international subjects, who either: (1) received placebo during the base study and continued in the Extension to receive a dose of GARDASIL (20/40/40/20 mcg formulation of qHPV vaccine) at Month 60 (plus 2 and 3 at Months 62 and 66, respectively, (2) received 3 doses of GARDASIL during the Base study and continued into the Extension to receive a fourth dose of GARDASIL at Month 60 for the purposes of investigating whether a fourth dose of vaccine (administered \\~4.5 years following completion of a 3-dose primary regimen) induces HPV 6, 11, 16, and 18 antibody responses that characterize immune therapy.\n\n* Serious Adverse Events (SAEs) were collected during Extension 1 and Extension 2. Note that the N includes only the 241 subjects vaccinated during the Extension Periods; of the 258 subjects that entered either Extension, 17 subjects discontinued before being vaccinated and therefore are not included in this table.","seriousNumAffected":1,"seriousNumAtRisk":241,"otherNumAffected":180,"otherNumAtRisk":241}],"seriousEvents":[{"term":"Appendicitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":282},{"groupId":"EG002","numAffected":0,"numAtRisk":292},{"groupId":"EG003","numAffected":0,"numAtRisk":146},{"groupId":"EG004","numAffected":1,"numAtRisk":146},{"groupId":"EG005","numAffected":0,"numAtRisk":241}]},{"term":"Kidney infection","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":282},{"groupId":"EG002","numAffected":0,"numAtRisk":292},{"groupId":"EG003","numAffected":0,"numAtRisk":146},{"groupId":"EG004","numAffected":1,"numAtRisk":146},{"groupId":"EG005","numAffected":0,"numAtRisk":241}]},{"term":"Pyelonephritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":282},{"groupId":"EG002","numAffected":1,"numAtRisk":292},{"groupId":"EG003","numAffected":0,"numAtRisk":146},{"groupId":"EG004","numAffected":0,"numAtRisk":146},{"groupId":"EG005","numAffected":0,"numAtRisk":241}]},{"term":"Drug toxicity","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":282},{"groupId":"EG002","numAffected":0,"numAtRisk":292},{"groupId":"EG003","numAffected":0,"numAtRisk":146},{"groupId":"EG004","numAffected":0,"numAtRisk":146},{"groupId":"EG005","numAffected":1,"numAtRisk":241}]},{"term":"Pancreatic carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":282},{"groupId":"EG002","numAffected":0,"numAtRisk":292},{"groupId":"EG003","numAffected":0,"numAtRisk":146},{"groupId":"EG004","numAffected":0,"numAtRisk":146},{"groupId":"EG005","numAffected":0,"numAtRisk":241}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":282},{"groupId":"EG002","numAffected":1,"numAtRisk":292},{"groupId":"EG003","numAffected":0,"numAtRisk":146},{"groupId":"EG004","numAffected":0,"numAtRisk":146},{"groupId":"EG005","numAffected":0,"numAtRisk":241}]},{"term":"Renal colic","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":282},{"groupId":"EG002","numAffected":0,"numAtRisk":292},{"groupId":"EG003","numAffected":0,"numAtRisk":146},{"groupId":"EG004","numAffected":0,"numAtRisk":146},{"groupId":"EG005","numAffected":0,"numAtRisk":241}]},{"term":"Cervix haemorrhage uterine","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":288},{"groupId":"EG001","numAffected":0,"numAtRisk":282},{"groupId":"EG002","numAffected":0,"numAtRisk":292},{"groupId":"EG003","numAffected":0,"numAtRisk":146},{"groupId":"EG004","numAffected":1,"numAtRisk":146},{"groupId":"EG005","numAffected":0,"numAtRisk":241}]}],"otherEvents":[{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":288},{"groupId":"EG001","numAffected":14,"numAtRisk":282},{"groupId":"EG002","numAffected":16,"numAtRisk":292},{"groupId":"EG003","numAffected":5,"numAtRisk":146},{"groupId":"EG004","numAffected":9,"numAtRisk":146},{"groupId":"EG005","numAffected":0,"numAtRisk":241}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":288},{"groupId":"EG001","numAffected":16,"numAtRisk":282},{"groupId":"EG002","numAffected":8,"numAtRisk":292},{"groupId":"EG003","numAffected":7,"numAtRisk":146},{"groupId":"EG004","numAffected":3,"numAtRisk":146},{"groupId":"EG005","numAffected":0,"numAtRisk":241}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":288},{"groupId":"EG001","numAffected":23,"numAtRisk":282},{"groupId":"EG002","numAffected":21,"numAtRisk":292},{"groupId":"EG003","numAffected":13,"numAtRisk":146},{"groupId":"EG004","numAffected":10,"numAtRisk":146},{"groupId":"EG005","numAffected":0,"numAtRisk":241}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":26,"numAtRisk":288},{"groupId":"EG001","numAffected":8,"numAtRisk":282},{"groupId":"EG002","numAffected":23,"numAtRisk":292},{"groupId":"EG003","numAffected":9,"numAtRisk":146},{"groupId":"EG004","numAffected":9,"numAtRisk":146},{"groupId":"EG005","numAffected":0,"numAtRisk":241}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":30,"numAtRisk":288},{"groupId":"EG001","numAffected":37,"numAtRisk":282},{"groupId":"EG002","numAffected":41,"numAtRisk":292},{"groupId":"EG003","numAffected":13,"numAtRisk":146},{"groupId":"EG004","numAffected":16,"numAtRisk":146},{"groupId":"EG005","numAffected":14,"numAtRisk":241}]},{"term":"Injection Site Erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":75,"numAtRisk":288},{"groupId":"EG001","numAffected":59,"numAtRisk":282},{"groupId":"EG002","numAffected":80,"numAtRisk":292},{"groupId":"EG003","numAffected":31,"numAtRisk":146},{"groupId":"EG004","numAffected":31,"numAtRisk":146},{"groupId":"EG005","numAffected":35,"numAtRisk":241}]},{"term":"Injection Site Haematoma","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":288},{"groupId":"EG001","numAffected":9,"numAtRisk":282},{"groupId":"EG002","numAffected":14,"numAtRisk":292},{"groupId":"EG003","numAffected":8,"numAtRisk":146},{"groupId":"EG004","numAffected":3,"numAtRisk":146},{"groupId":"EG005","numAffected":0,"numAtRisk":241}]},{"term":"Injection Site Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":245,"numAtRisk":288},{"groupId":"EG001","numAffected":247,"numAtRisk":282},{"groupId":"EG002","numAffected":263,"numAtRisk":292},{"groupId":"EG003","numAffected":105,"numAtRisk":146},{"groupId":"EG004","numAffected":114,"numAtRisk":146},{"groupId":"EG005","numAffected":180,"numAtRisk":241}]},{"term":"Injection Site Swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":80,"numAtRisk":288},{"groupId":"EG001","numAffected":74,"numAtRisk":282},{"groupId":"EG002","numAffected":95,"numAtRisk":292},{"groupId":"EG003","numAffected":23,"numAtRisk":146},{"groupId":"EG004","numAffected":29,"numAtRisk":146},{"groupId":"EG005","numAffected":46,"numAtRisk":241}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":288},{"groupId":"EG001","numAffected":17,"numAtRisk":282},{"groupId":"EG002","numAffected":15,"numAtRisk":292},{"groupId":"EG003","numAffected":7,"numAtRisk":146},{"groupId":"EG004","numAffected":9,"numAtRisk":146},{"groupId":"EG005","numAffected":0,"numAtRisk":241}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":288},{"groupId":"EG001","numAffected":23,"numAtRisk":282},{"groupId":"EG002","numAffected":20,"numAtRisk":292},{"groupId":"EG003","numAffected":17,"numAtRisk":146},{"groupId":"EG004","numAffected":9,"numAtRisk":146},{"groupId":"EG005","numAffected":0,"numAtRisk":241}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":288},{"groupId":"EG001","numAffected":10,"numAtRisk":282},{"groupId":"EG002","numAffected":8,"numAtRisk":292},{"groupId":"EG003","numAffected":9,"numAtRisk":146},{"groupId":"EG004","numAffected":1,"numAtRisk":146},{"groupId":"EG005","numAffected":0,"numAtRisk":241}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":288},{"groupId":"EG001","numAffected":6,"numAtRisk":282},{"groupId":"EG002","numAffected":4,"numAtRisk":292},{"groupId":"EG003","numAffected":7,"numAtRisk":146},{"groupId":"EG004","numAffected":9,"numAtRisk":146},{"groupId":"EG005","numAffected":0,"numAtRisk":241}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":117,"numAtRisk":288},{"groupId":"EG001","numAffected":103,"numAtRisk":282},{"groupId":"EG002","numAffected":116,"numAtRisk":292},{"groupId":"EG003","numAffected":74,"numAtRisk":146},{"groupId":"EG004","numAffected":53,"numAtRisk":146},{"groupId":"EG005","numAffected":60,"numAtRisk":241}]},{"term":"Dysmenorrhoea","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":288},{"groupId":"EG001","numAffected":8,"numAtRisk":282},{"groupId":"EG002","numAffected":13,"numAtRisk":292},{"groupId":"EG003","numAffected":15,"numAtRisk":146},{"groupId":"EG004","numAffected":6,"numAtRisk":146},{"groupId":"EG005","numAffected":0,"numAtRisk":241}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":288},{"groupId":"EG001","numAffected":10,"numAtRisk":282},{"groupId":"EG002","numAffected":17,"numAtRisk":292},{"groupId":"EG003","numAffected":11,"numAtRisk":146},{"groupId":"EG004","numAffected":10,"numAtRisk":146},{"groupId":"EG005","numAffected":0,"numAtRisk":241}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."},"pointOfContact":{"title":"Senior Vice President,Global Clinical Development","organization":"Merck Sharp & Dohme Corp.","email":"ClinicalTrialsDisclosure@merck.com","phone":"1-800-672-6372"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D030361","term":"Papillomavirus Infections"},{"id":"D005831","term":"Genital Diseases, Female"}],"ancestors":[{"id":"D015229","term":"Sexually Transmitted Diseases, Viral"},{"id":"D012749","term":"Sexually Transmitted Diseases"},{"id":"D003141","term":"Communicable Diseases"},{"id":"D007239","term":"Infections"},{"id":"D004266","term":"DNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D014412","term":"Tumor Virus Infections"},{"id":"D000091662","term":"Genital Diseases"},{"id":"D000091642","term":"Urogenital Diseases"},{"id":"D020969","term":"Disease Attributes"},{"id":"D010335","term":"Pathologic Processes"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"},{"id":"D052776","term":"Female Urogenital Diseases"},{"id":"D005261","term":"Female Urogenital Diseases and Pregnancy Complications"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068857","term":"Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18"}],"ancestors":[{"id":"D017778","term":"Vaccines, Combined"},{"id":"D014612","term":"Vaccines"},{"id":"D001688","term":"Biological Products"},{"id":"D045424","term":"Complex Mixtures"},{"id":"D053918","term":"Papillomavirus Vaccines"},{"id":"D014765","term":"Viral Vaccines"}]}},"hasResults":true}